A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours

NCT04525638 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Tumours (NET)
Neuroendocrine Carcinomas (NEC)

Interventions

DRUG: 177Lu-Dotatate
DRUG: Nivolumab

Sponsor

Fundación de investigación HM

Collaborators

[object Object]